Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan

[1] Acosta FJ(2012)Medication adherence in schizophrenia World J Psychiatry 2 74-82

[2] Hernández JL(2007)Nonadherence to antipsychotic treatment in patients with schizophrenic disorders Neuro Endocrinol Lett 28 95-116

[3] Pereira J(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-218

[4] Herrera J(2008)Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia BMC Psychiatry 8 32-56

[5] Rodríguez CJ(2004)Practice guideline for the treatment of patients with schizophrenia Am J Psychiatry 161 1-324

[6] Svestka J(2010)Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines J Psychiatr Pract 16 306-768

[7] Bitter I(2015)Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge J Manag Care Spec Pharm 21 754-428

[8] Higashi K(2015)Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole Schizophr Res 161 421-213

[9] Medic G(2014)Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials Schizophr Bull 40 192-1180

[10] Littlewood KJ(2013)Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia Patient Prefer Adherence 7 1171-619

[1] Acosta FJ(2012)Medication adherence in schizophrenia World J Psychiatry 2 74-82

[2] Hernández JL(2007)Nonadherence to antipsychotic treatment in patients with schizophrenic disorders Neuro Endocrinol Lett 28 95-116

[3] Pereira J(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-218

[4] Herrera J(2008)Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia BMC Psychiatry 8 32-56

[5] Rodríguez CJ(2004)Practice guideline for the treatment of patients with schizophrenia Am J Psychiatry 161 1-324

[6] Svestka J(2010)Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines J Psychiatr Pract 16 306-768

[7] Bitter I(2015)Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge J Manag Care Spec Pharm 21 754-428

[8] Higashi K(2015)Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole Schizophr Res 161 421-213

[9] Medic G(2014)Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials Schizophr Bull 40 192-1180

[10] Littlewood KJ(2013)Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia Patient Prefer Adherence 7 1171-619